The Latest Breaking News from Humira

After Humira’s patent cliff, what do analysts think about AbbVie’s stock now?

We have all seen them time and time again: the overly cheerful people jogging through parks, painting fences, or laughing over salads while a voice calmly lists horrifying side effects like “possible internal bleeding” and “sudden death.” Drug commercials are a strange blend of optimism and danger, and sometimes they…

Patients who take the autoimmune disease treatment Humira may see some price relief when several lower-cost, biosimilar versions of the AbbVie drug reach the U.S. market in July

U.S. doctors can now choose Amjevita instead, the first of several close copies of the popular rheumatoid arthritis drug expected this year. But industry-watchers warn consumer savings may be limited.

CHICAGO — One of the most popular prescription medications in the world is about to face fierce competition in the U.S. — something that could mean lower prices for the drug but a difficult coming year for the Illinois company that makes it.

Cigna Corp (NYSE: CI) is poised to benefit from the launch of bioequivalent Humira in July 2023, according to Morgan Stanley.

AbbVie Inc (NYSE:ABBV) reports Q1 adjusted EPS of $3.16, higher than the $2.89 reported a year ago and beating the consensus of $3.14. Overall sales increased 4.1% Y/Y (5.4% on an operational basis) to $13.54 billion, missing the consensus of $13.63 billion. The immunology portfolio generated $6.14 billion in sales, +6.9% (+8.1%…

Here's a roundup of top developments in the biotech space over the last 24 hours.